An invariant feature of the pathological cascade in Alzheimer's diseases (AD) is a reactive gliosis, reflecting an underlying alteration in the innate immune activation state within the brain. Innate immune signaling is altered early in AD, but is also skewed towards an activated state as a consequence of brain aging. There is strong genetic evidence that innate immunity has a significant role in AD. Variants in two genetic loci that play roles in the complement cascade, CR1 and CLU, show significant genetic associations with AD, and rare coding variants in TREM2 also confer substantial risk for AD. Numerous experimental studies in AD mouse models show that manipulating innate immune pathways can have positive or negative effects on proteostasis, cognition and neurodegeneration. At least when assessing A? pathology as an endpoint, the beneficial effects of some innate immune system manipulations are robust. We propose to identify therapeutic targets within the innate immune signaling cascade in AD that could be safely manipulated to provide disease modification in AD. However, because of the complexity of, and the gaps in our knowledge regarding, innate immune signaling within the CNS, a systems level approach that integrates multiple types of data will be required to achieve this goal. Indeed, development of any innate immune therapy will need to be finely tuned and extensively validated in order to be further developed as a potential AD therapy. We will use a multifaceted systems level approach to identify targets within innate immune signaling pathways that can safely provide disease modifying effects in AD. Comprehensive, transcriptomic, genetic and pathological data from both humans and mouse models will be generated, integrated and analyzed in novel ways. This integrated data will then be used to guide multiple preclinical target validation studies of key innate immune targets in both APP and tau mouse models as well as non-transgenic mice. These studies will dramatically accelerate the identification and validation of disease modifying innate immune modulatory strategies in AD and will provide important insights into how these various manipulations of innate immune activation states alter normal behaviors with an emphasis on cognition.

Public Health Relevance

Finding effective therapy for Alzheimer's Disease is a huge unmet medical need. The proposed studies will provide key information that will guide development of innate immune therapies. They will provide the rationale and preclinical validation for further development of novel therapies harnessing innate immunity that could target multiple pathologies relevant to Alzheimer's disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AG046139-02
Application #
8735841
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Petanceska, Suzana
Project Start
2013-09-20
Project End
2018-08-31
Budget Start
2014-09-15
Budget End
2015-08-31
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Florida
Department
Neurosciences
Type
Schools of Medicine
DUNS #
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Dickson, Dennis W; Heckman, Michael G; Murray, Melissa E et al. (2018) APOE ?4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology 91:e1182-e1195
Liesinger, Amanda M; Graff-Radford, Neill R; Duara, Ranjan et al. (2018) Sex and age interact to determine clinicopathologic differences in Alzheimer's disease. Acta Neuropathol 136:873-885
Chakrabarty, Paramita; Li, Andrew; Ladd, Thomas B et al. (2018) TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer's disease. J Exp Med 215:2247-2264
Whitwell, Jennifer L; Graff-Radford, Jonathan; Tosakulwong, Nirubol et al. (2018) [18 F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. Ann Neurol 83:248-257
Golde, Todd E; DeKosky, Steven T; Galasko, Douglas (2018) Alzheimer's disease: The right drug, the right time. Science 362:1250-1251
Chung, Jaeyoon; Zhang, Xiaoling; Allen, Mariet et al. (2018) Genome-wide pleiotropy analysis of neuropathological traits related to Alzheimer's disease. Alzheimers Res Ther 10:22
Moore, Brenda D; Martin, Jason; de Mena, Lorena et al. (2018) Short A? peptides attenuate A?42 toxicity in vivo. J Exp Med 215:283-301
Blechingberg, Jenny; Poulsen, Annemarie Svane Aavild; Kjølby, Mads et al. (2018) An alternative transcript of the Alzheimer's disease risk gene SORL1 encodes a truncated receptor. Neurobiol Aging 71:266.e11-266.e24
Kidana, Kiwami; Tatebe, Takuya; Ito, Kaori et al. (2018) Loss of kallikrein-related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice. EMBO Mol Med 10:
Sorrentino, Zachary A; Xia, Yuxing; Funk, Cory et al. (2018) Motor neuron loss and neuroinflammation in a model of ?-synuclein-induced neurodegeneration. Neurobiol Dis 120:98-106

Showing the most recent 10 out of 61 publications